Hodgkin disease in ataxia-telangiectasia patients with poor outcomes
✍ Scribed by Sandoval, Claudio ;Swift, Michael
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 66 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
To determine the presenting clinicopathologic features and treatment outcomes of 11 ataxia‐telangiectasia (A‐T) patients with Hodgkin disease.
Procedure
We reviewed the charts of 412 A‐T patients to ascertain cases of Hodgkin disease. The data analyzed included date of diagnosis, duration of symptoms, chest radiographic findings, stage and histology, therapy, and outcome.
Results
The six male and five female patients had a median age at diagnosis of 12.2 years. Eight patients presented with fever, cough, and/or cervical lymphadenopathy with a median duration of symptoms of 3 months. Five patients had abnormal chest radiographic findings a median of 3 months prior to diagnosis and were treated with antibiotics for presumed pneumonia. Mediastinal and hilar adenopathy in addition to bilateral infiltrates were present. Histopathology reports were available for nine patients. Three had nodular sclerosing and two each had lymphocyte depleted, mixed cellularity, and not otherwise specified histology. Eight patients had stage IV disease, one had stage III, and in two the staging was not documented. Six patients received reduced‐dose chemotherapy, two received radiation therapy, two did not receive therapy, and in one the treatment was not documented. In no patient did the Hodgkin disease remit and all died with a median survival of 3 months. Eight died of pneumonia and three of multiple system organ failure.
Conclusions
A‐T patients with Hodgkin disease have markedly reduced survival compared to Hodgkin disease in the general population. Their poor outcomes may be due to advanced Hodgkin disease, failure to recognize coincident chronic lung disease, and the use of non‐standard treatment regimens. Med Pediatr Oncol 2003;40:162–166. © 2003 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Background. Patients with ataxia-telangiectasia (A-T) are at an increased risk for developing lymphoid malignancies, yet the appropriate therapy remains unknown. Radiation therapy at conventional doses results in destruction of normal tissue, which has suggested that full-dose chemotherapy might res
## Abstract ## BACKGROUND Endostatin is a cleaved fragment of collagen Type XVIII and has antiangiogenic activity. The clinical significance of circulating, soluble endostatin (S‐endostatin) is not known. ## METHODS Pretreatment S‐endostatin and serum vascular endothelial growth factor (S‐VEGF)
The outcome of Hodgkin's disease in elderly patients is a subject of controversy. We analysed retrospectively 31 cases of patients older than 60 years that received treatment according to current protocols. We observed a CR rate of 87 per cent and survival of 58 per cent with a median follow-up of 5